bioAffinity Technologies Inc. Common Stock (BIAF)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I look for durable earnings, honest accounting, and a margin of safety. bioAffinity fails most tests. It has no profits: in fiscal year 2023, the period ended 2023-12-31, net loss was $7.9M; in fiscal year 2024, the period ended 2024-12-31, net loss was $9.0M; and in fiscal year 2025, the period ended 2025-12-31, net loss was $14.9M. Revenue actually fell from $9.4M in fiscal year 2024 to $6.2M in fiscal year 2025. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $1.5M and net loss was $3.4M, a -222.83% margin. Trailing free cash flow is -$11.6M, a -39.4% FCF yield on a $29.4M market cap. FairStock calculates P/E at -2.69, P/B at 0.43, ROE at -1860.15%, ROCE at -125.11%, Piotroski F-Score at 4/9, and Altman Z-Score at -10.37. A sub-book price may attract asset hunters, but book value is not protected when the company consumes cash. The Lynch category is none because it lost money in each of the last four years. The business sells CyPath lung, a non-invasive diagnostic, but the figures show no earnings power or moat—just R&D and lab services with 57 employees and shrinking revenue. At $3.63, this is not a Graham bargain; it is a speculative cash-burn story.

In plain English: bioAffinity Technologies is a small healthcare company trying to develop and sell non-invasive tests for early lung cancer. The business looks weak right now: it has lost money for years, revenue fell in fiscal year 2025, and the latest quarter still had a big loss. At $3.63 on 2026-10-13, the price looks low compared with its accounting value, but the company is burning cash, so cheap is not the same as safe.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer